Table 1: Evaluation of 12 “range finding” post-biochemical failure risk categorization (BFRC) schemes in univariable competing risk models for prostate cancer-specific mortality (PCSM) after biochemical failure based on historical prognostic cutpoints for PSA doubling time and time to biochemical failure.

High riskLow riskBFRC performance
PSADTTTBFPSADTTTBFc-index (95% CI)Ranking value

<3<1>9>30.724(0.684–0.764)1
<3<2>9>40.705(0.668–0.743)40.095§
<3<3>9>50.685(0.651–0.719)80.001
<3<1>12>30.720(0.680–0.760)20.489§
<3<2>12>40.695(0.657–0.733)50.026
<3<3>12>50.667(0.634–0.700)9<0.001
<6<1>15>30.714(0.680–0.749)30.27§
<6<2>15>40.691(0.658–0.725)60.033
<6<3>15>50.659(0.629–0.689)11<0.001
<9<1>18>30.690(0.656–0.723)70.003
<9<2>18>40.664(0.633–0.695)10<0.001
<9<3>18>50.630(0.603–0.658)12<0.001

PSA: prostate-specific antigen; BFRC: biochemical failure risk categorization; PSADT: PSA doubling time (months); TTBF: time from biochemical (Phoenix) failure (years); CI: confidence interval; c-index: Harrell’s concordance index.
Risk is defined by PSADT and/or TTBF ranges specified.
Performance assessed by c-index, ranked highest (best) to lowest (worst). Performance against best BFRC compared using paired Student’s -test.
§c-index not significantly lower than best BFRC.